Capecitabine and pyrotinib for HER2-positive breast cancer after ADC therapy
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two oral medications, capecitabine (a chemotherapy pill) and pyrotinib (a targeted therapy), for people with HER2-positive breast cancer that has spread and has already been treated with an antibody-drug conjugate (ADC). The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have HER2-positive breast cancer that has spread to other parts of the body.
- You have already been treated with an antibody-drug conjugate (ADC) like T-DXd, T-DM1, or SHR-A1811, and either the cancer grew during that treatment or you stopped it due to side effects, cost, or personal choice without the cancer growing.
- You are able to perform daily activities (ECOG performance status 0-2).
- Your major organs (like liver, kidneys, heart) are working well enough.
- You have not previously taken a TKI (like lapatinib, neratinib, or pyrotinib) or capecitabine (or other fluoropyrimidine chemotherapy) for advanced or metastatic breast cancer.
- You do not have a known deficiency of the enzyme DPD (which affects how your body processes capecitabine).
- You are not pregnant or breastfeeding.
- You have not had another cancer in the past 5 years, except for cured basal cell skin cancer or cervical carcinoma in situ.
- You do not have serious medical or mental conditions that would increase trial risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking pyrotinib (a daily pill) with capecitabine (another pill) after breast cancer surgery can help prevent HER2-positive early-stage breast cancer from coming back. It is for women who have already had their cancer removed and meet certain risk criteria.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This study compares a new antibody-drug conjugate (SHR-A1811) with a combination of two oral drugs (pyrotinib and capecitabine) for women with HER2-positive advanced breast cancer that has stopped responding to trastuzumab (Herceptin). It aims to see which treatment works better.
This trial tests a targeted drug called pyrotinib for women with HER2-positive breast cancer that hasn't spread far. It aims to see if adding this drug to standard treatment helps improve outcomes before and after surgery.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This trial studies whether adding pyrotinib and capecitabine after surgery can lower the risk of cancer coming back in people with very small, lymph-node–negative, HER2-positive breast cancer. It’s for patients who fit specific tumor size and HER2 test results and who can safely take chemotherapy-like medicines and stay on contraception during treatment.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.